This trial is completed!
Search for a recruiting clinical trial for your condition
You can access this
clinical trial
if you have
Hepatitis C Virus Infection
and you are
over 18
years old
2
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

This study will evaluate the efficacy, safety, and tolerability of sofosbuvir /velpatasvir (SOF/VEL) fixed-dose combination (FDC) in participants with chronic hepatitis C virus (HCV) who have received a liver transplant.

Provided treatments

  • Drug: SOF/VEL
Tris trial is registered with FDA with number: NCT02781571. The sponsor of the trial is Gilead Sciences and it is looking for 79 volunteers for the current phase.
Official trial title:
A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination in Subjects With Chronic HCV Infection Who Have Received a Liver Transplant